China sentences 9 in fentanyl trafficking case after US tip

Image
AP Xingtai
Last Updated : Nov 07 2019 | 2:15 PM IST

A Chinese court sentenced nine fentanyl traffickers Thursday in a case that was a culmination of a rare collaboration between Chinese and US law enforcement to crack down on global networks that manufacture and distribute lethal synthetic opioids.

Liu Yong was sentenced to death with a two-year reprieve, while Jiang Juhua and Wang Fengxi were sentenced to life in prison. Six other members of the operation got lesser sentences, ranging from six months to ten years.

Working off a 2017 tip from the US Department of Homeland Security about an online drug vendor who went by the name Diana, Chinese police busted a drug ring based in the northern Chinese city of Xingtai that shipped synthetic drugs to the US and other countries from a gritty clandestine laboratory.

They arrested more than 20 criminal suspects and seized 11.9 kilograms (26.23 pounds) of fentanyl as well as 19.1 kilograms (42.11 pounds) of other drugs.

In form, the enterprise resembled a small business, with a perky sales force that spoke passable English, online marketing, contract manufacturing, and a sophisticated export operation, according to U.S. and Chinese law enforcement.

But the business had grave implications. Police photographs of the seizure show a dingy, chaotic scene, with open containers of unidentified chemicals and Chinese police in rubber gloves and breathing masks.

Liu and Jiang were accused of manufacturing and trafficking illicit drugs. The others were accused of trafficking. Death sentences are almost always commuted to life in prison after the reprieve.

Chinese officials said the Xingtai case was one of three fentanyl trafficking networks they are pursuing based on U.S. intelligence, but declined to discuss the details of the other cases, which are ongoing.

Austin Moore, an attach to China for the US Homeland Security Department, said the Xingtai case was "an important step" showing that Chinese and U.S. investigators have the capacity to collaborate across international borders.

Scrambling to contain surging overdose deaths, Washington has blamed Beijing for failing to curb the supply of synthetic drugs that US officials say come mainly from China. In August, President Donald Trump lashed out at Chinese President Xi Jinping for failing to do more to combat illicit opioid distribution in China's vast, freewheeling chemicals industry. US officials have reportedly moved to link Beijing's efforts on fentanyl to U.S. trade talks.

Yu Haibin, deputy director of the Office of China National Narcotics Control Commission, on Thursday called allegations that Chinese supply is at the root of America's opioid problem "irresponsible and inconsistent with the actual facts." "Drug crime is the public enemy of all humankind," he added. "It's about the life of human beings. It should not be related with the trade war or other political reasons." Chinese officials have been at pains to emphasize the efforts they have made to expand drug controls and crack down on illicit suppliers, even though synthetic opioid abuse is not perceived to be a significant problem in China.

But prosecuting cases against a new, rising class of Chinese synthetic drug kingpins has remained a challenge. Profit-seeking chemists have adroitly exploited regulatory loopholes by making small changes to the chemical structure of banned substances to create so-called analogs that are technically legal.

US officials have been hopeful that China's move earlier this year to outlaw unsanctioned distribution of all fentanyl-like drugs as a class will help constrain supply and make it easier to prosecute Chinese dealers.

According to the U.S. Centers for Disease Control and Prevention, more than 500,000 Americans died of drug overdoses in the decade ending in 2017 increasingly, from synthetic opioids like the ones sold by the Xingtai network.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 07 2019 | 2:15 PM IST

Next Story